BCG is not a defined strain but a family of regional substrains with marked genetic differences. In this Review, the authors discuss the mechanisms by which BCG immunotherapy induces its antitumour activity and treatment-limiting toxicity, and the effect that genetic and phenotypic differences between BCG substrains might have on these effects.
- Christine Gan
- Hugh Mostafid
- David J. M. Lewis